Advanced Institute of NBIC Integrated Drug Discovery and Development, East China Normal University, North Zhongshan Road #3663, Shanghai, 200062, People's Republic of China.
Inflamm Res. 2010 May;59(5):323-34. doi: 10.1007/s00011-010-0163-y. Epub 2010 Feb 7.
Emerging evidence indicates an association of the acute-phase protein serum amyloid A (SAA) with obesity. Here we review and summarize quantitatively the available data related to this association.
PubMed was systematically searched using the terms "serum amyloid A" and "obesity." Eighty-one relevant studies between January 1966 and July 2009 were identified. Of these, only 11 cross-sectional studies and 10 prospective studies with successful interventions met our inclusion criteria for the meta-analysis. All analyses were conducted using the Comprehensive Meta-Analysis software. Literature pertaining to the relationship between SAA and other inflammatory markers, and the association between SAA and obesity-related disorders, such as cardiovascular diseases, atherosclerosis, diabetes, and insulin resistance was also reviewed.
A strong association between body mass index and SAA levels was found in the 11 cross-sectional studies. The overall correlation coefficient is 0.230 (95% CI 0.160-0.297, P < 0.0005). The ten prospective studies were subsequently analyzed, and the difference in SAA levels before and after weight loss, expressed as standardized mean difference was -0.480 (95% CI -0.678 to -0.283, P < 0.0005). We discuss some potential underlying mechanisms and clinical applications for reducing SAA levels in obesity.
新出现的证据表明,急性期蛋白血清淀粉样蛋白 A(SAA)与肥胖有关。在这里,我们回顾和总结了与这一关联相关的现有数据。
使用术语“血清淀粉样蛋白 A”和“肥胖”系统地搜索了 PubMed。确定了 1966 年 1 月至 2009 年 7 月之间的 81 项相关研究。其中,只有 11 项横断面研究和 10 项有成功干预的前瞻性研究符合我们的荟萃分析纳入标准。所有分析均使用 Comprehensive Meta-Analysis 软件进行。还回顾了与 SAA 与其他炎症标志物之间的关系以及 SAA 与肥胖相关疾病(如心血管疾病、动脉粥样硬化、糖尿病和胰岛素抵抗)之间的关系的文献。
在 11 项横断面研究中发现了体重指数与 SAA 水平之间的强烈关联。总体相关系数为 0.230(95%置信区间 0.160-0.297,P < 0.0005)。随后对 10 项前瞻性研究进行了分析,体重减轻前后 SAA 水平的差异,以标准化均数差表示为-0.480(95%置信区间-0.678 至-0.283,P < 0.0005)。我们讨论了一些潜在的机制和临床应用,以降低肥胖症患者的 SAA 水平。